Efficacy or convenience? Subcutaneous blinatumomab as a promising new treatment for B-cell acute lymphoblastic leukaemia

Affiliations

¹ Department of Internal Medicine, Division of Hematology & Oncology, University of Cincinnati Cancer Center, Cincinnati, OH 45267, USA. Electronic address: curraney@ucmail.uc.edu.

Comment

Emily Curran. Lancet Haematol. 2025 Jul.

. 2025 Jul;12(7):e485-e487.

doi: 10.1016/S2352-3026(25)00169-3.

¹ Department of Internal Medicine, Division of Hematology & Oncology, University of Cincinnati Cancer Center, Cincinnati, OH 45267, USA. Electronic address: curraney@ucmail.uc.edu.

No abstract available

Conflict of interest statement

I declare no competing interests.

Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: post-hoc safety and activity analysis from a multicentre, single-arm, phase 1/2 trial.
Jabbour E, Lussana F, Martínez-Sánchez P, Torrent A, Rifón JJ, Agrawal V, Tormo M, Cassaday RD, Cluzeau T, Huguet F, Papayannidis C, Hernández-Rivas JM, Rijneveld A, Fleming S, Vucinic V, Böll B, Ikezoe T, Abdul-Hay M, Savoie ML, Schuh AC, Berthon C, Schwartz S, Chiaretti S, Yuda J, Miyazaki T, González-Campos J, Chen Y, Wong H, Choudhry J, Zugmaier G, Guest E, Gordon P, Kantarjian H. Jabbour E, et al. Lancet Haematol. 2025 Jul;12(7):e529-e541. doi: 10.1016/S2352-3026(25)00144-9. Epub 2025 Jun 15. Lancet Haematol. 2025. PMID: 40532723 Clinical Trial.